Environmental and Behavioral Factors in Infertility and ART Outcomes
Condition(s) studied
Investigational drug(s) / intervention(s)
plastic products: Environmental pollutants related to plastic products
None exposure: No environmental pollutants related to plastic products
Study summary
This large-scale study aims to understand how everyday environment and lifestyle may affect the success of fertility treatments like IVF. The main idea is that exposure to certain environmental chemicals (e.g., from plastics or air pollution) and personal habits (e.g., diet, stress) could be linked to whether these treatments result in a successful pregnancy and live birth.
The study will follow approximately 5,000 couples undergoing fertility treatment in Hunan, China. Participants will answer questionnaires about their health, lifestyle, and environment and provide small biological samples (like blood and urine) during their standard treatment process. Their treatment outcomes will be tracked anonymously.The goal is to identify factors that might lower the chances of treatment success. This knowledge could help future patients and doctors make informed decisions and could guide public health advice on reducing potential risks. The study has received ethical approval, and all participant information will be kept strictly confidential.
Eligibility
Primary outcome measure(s)
- Live birth rate following the first ART cycle — Within 24 months from the initiation of the first ART cycle
The proportion of participants achieving at least one live birth (gestational age ≥ 28 weeks) after the initiation of their first ART treatment cycle.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Reproductive Medicine Center of Xiangya Third Hospital of Central South University | Changsha | Hunan | Recruiting |
More The Third Xiangya Hospital of Central South University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07384676 on ClinicalTrials.gov ↗ ← All trials in China